Suppr超能文献

自体造血干细胞移植后长期存活的患者,在移植多年后,其针对可通过疫苗预防的疾病的体液免疫存在显著缺陷。

Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant.

机构信息

Department of Infection, Immunity and Cardiovascular Diseases and the Florey Institute for Host-Pathogen Interactions, University of Sheffield, UK; South Yorkshire Regional Department of Infection & Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

Specialised Cancer Services, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.

出版信息

Vaccine. 2021 Aug 9;39(34):4778-4783. doi: 10.1016/j.vaccine.2021.07.022. Epub 2021 Jul 20.

Abstract

Current international guidelines recommend routinely vaccinating haematopoetic stem cell transplant (HSCT) recipients. Despite significant infection-related mortality following autologous HSCT, routine vaccination programmes (RVP) completion is poor. For recovered HSCT recipients, it is uncertain whether catch-up vaccination remains worthwhile years later. To determine potential susceptibility to vaccine preventable infections, we measured antibody titres in 56 patients, a median of 7 years (range 0-29) following autologous HSCT, who had not completed RVP. We found that almost all participants had inadequate titres against diphtheria (98.2%) and pneumococcal infection (100%), and a significant proportion had inadequate titres against measles (34.5%). Of those subsequently vaccinated according to available guidelines, many mounted adequate serological responses. These data suggest a pragmatic catch-up approach for autologous HSCT recipients who have not completed RVP is advisable, with universal vaccination against some pathogens (e.g. Streptococcus pneumoniae and diphtheria) and serologically-guided approaches for others (e.g. measles and varicella zoster virus).

摘要

目前的国际指南建议对造血干细胞移植(HSCT)受者进行常规疫苗接种。尽管自体 HSCT 后与感染相关的死亡率很高,但常规疫苗接种计划(RVP)的完成情况很差。对于已康复的 HSCT 受者,多年后补种疫苗是否仍然有价值尚不确定。为了确定对疫苗可预防感染的潜在易感性,我们在自体 HSCT 后中位数为 7 年(范围为 0-29 年)的 56 名未完成 RVP 的患者中测量了抗体滴度。我们发现,几乎所有参与者对白喉(98.2%)和肺炎球菌感染(100%)的抗体滴度不足,并且有相当比例的人对麻疹(34.5%)的抗体滴度不足。根据现有指南随后进行疫苗接种的患者中,许多人产生了足够的血清学反应。这些数据表明,对于未完成 RVP 的自体 HSCT 受者,采取实用的补种方法是明智的,对于某些病原体(例如肺炎链球菌和白喉)进行普遍疫苗接种,并对其他病原体(例如麻疹和风疹病毒)进行血清学指导的方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验